PROFILE-1001

NCT00585195 📎

Regimen

Experimental
crizotinib 250 mg BID

Population

50 patients with ROS1-rearranged advanced NSCLC (phase 1 expansion cohort)

Key finding

ORR 72% (95% CI 58-84); mPFS 19.2 mo; mDOR 17.6 mo; 50 ROS1+ patients established crizotinib as ROS1+ NSCLC standard

Source: PMID 25264305

Timeline

  • Publication: 2014-11-20 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.210)